Amoxiclav

PreclinicalSmall molecule

Pfizer

Amoxiclav is one of 39 small molecule programs targeting Pneumonia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaActive, not recruiting

Maxillary SinusitisActive, not recruiting

PneumoniaPreclinical

Active, not recruiting

Maxillary SinusitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

155 competitors in Pneumonia

#DrugCompanyPhaseTrials

Acanya

Pfizer

Preclinical

1 2

Prevacid

Takeda

Preclinical

1 3

Plaquenil

Jazz Pharmaceuticals

Preclinical

1 4

Innohep

Jazz Pharmaceuticals

Preclinical

1 5

Avlosulfon

AAlmirall, S.A.

Preclinical

4 6

Zantac 150

CChattem

Preclinical

2 7

Ofev

Boehringer Ingelheim

Preclinical

1 8

Mucinex

RReckitt Benckiser LLC

Preclinical

1 9

Cancidas

FFresenius Kabi Taiwan Ltd.

Preclinical

1 10

Biological Check-up

UUniversity Hospital, Bordeaux

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pneumonia1 trial

Non-Interventional Open Label Prospective Observational Comparative Study On Evaluation Of Compliance Of The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Mild To Moderate Community Acquired Pneumonia

Terminated· Pfizer logo

Pfizer··NCT01032694·30 enrolled

Maxillary Sinusitis1 trial

Non-Interventional Open Label Prospective Comparative Observational Study Of Evaluation Of Compliance In The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Of Acute Bacterial Maxillary Sinusitis

Completed· Pfizer logo

Pfizer··NCT01032174·123 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Amoxiclav. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Amoxiclav compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Amoxiclav. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Pfizer

Amoxiclav

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pneumonia1 trial

Maxillary Sinusitis1 trial

References

Drug Info

Quick Facts

Related News